Wells Fargo upgraded Spyre Therapeutics to Overweight from Equal Weight with a price target of $35, up from $12.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on SYRE:
- Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Spyre Therapeutics Revamps Governance and Fiscal Year
- Spyre Therapeutics Announces Board Changes and Compensation Updates
- Spyre Therapeutics Enhances Protection for Executives and Board
- 3 Best Stocks to Buy Now, 1/16/2024, According to Top Analysts